Lumida
/MMC
⌘K
Marsh & McLennan Companies Inc

Marsh & McLennan Companies Inc

MMC
$182.70USD-1.58%-2.93 today

MARKET CAP

89.5B

P/E (TTM)

21.7x

FWD P/E

DAY RANGE

$182 – $185

52W RANGE

$174
$248

AI Summary

Stalk
Sell NowMedium

MMC's price has decisively broken below the $185 support level on expanding volume and remains below the 9/20/50 and 200 SMAs, indicating sellers in control. Stage 4 decline permissions and the active Support Failure pattern reinforce a bearish medium-term bias. Short-term conditions also favor downside as price sits below all key EMAs. Execution via Sell Now is appropriate, targeting rallies into the former support zone now acting as resistance around the EMA cluster. A decisive close back above the broken support and EMA cluster would invalidate this stance.

  • Recent CR3 Partners acquisition and Mercer-Syndio partnership enhance service suite.
  • Oliver Wyman’s AI integration drives efficiency and client growth.
  • Current high P/E raises correction risk if growth underperforms.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Marsh & McLennan (MRSH) is a leading global professional services firm specializing in risk management, insurance brokerage, and consulting services. The company operates through several major businesses, including Marsh, Guy Carpenter, Mercer, and Oliver Wyman. Positioned within the insurance and consulting sectors, Marsh & McLennan is benefitting from the increasing demand for integrated risk and insurance solutions, particularly as organizations seek to navigate the complexities of a post-pandemic world and capitalize on digital transformation, including AI integration.

Bull says

  • Recent CR3 Partners acquisition and Mercer-Syndio partnership enhance service suite.
  • Oliver Wyman’s AI integration drives efficiency and client growth.
  • Median analyst target of $206 implies 26% upside from $163.25.
  • Diversified revenue streams stabilize earnings across insurance and consulting.
  • High earnings yield and positive profitability factors suggest value.
  • Moderate momentum and strong trading liquidity reflect investor confidence.

Bear says

  • Current high P/E raises correction risk if growth underperforms.
  • Competition from Aon, WLTW, Accenture intensifies market share pressure.
  • Economic downturn may cut demand for consulting and insurance.
  • Elevated leverage risk and weak growth metrics could strain cash flow.
  • Rising short interest signals growing investor skepticism.
  • CR3 integration may face execution hurdles, limiting expected synergies.